Scalability Strategies for Cell and Gene Therapy Production

We can’t scale CAR-T with the current centralized manufacturing mindset. ZS Associates conducted a deep-dive on decentralized manufacturing for autologous CAR-T therapies, and it confirms what many have suspected for years: Centralized production doesn’t match the biology or the economics. Here are the big observations from the analysis: 1. Decentralization is possible - and it’s necessary. - Current costs of a single CAR-T batch manufactured centrally? $250K–$380K. - Much of that is upfront fixed cost (CAPEX, IT, asset maintenance). - Decentralized platforms should shift that model toward lower-risk OPEX, allowing for faster, leaner delivery near the bedside. 2. Cold chain logistics are killing your lead times. - Long-distance transport introduces bottlenecks, handoffs, and storage risk. - Local manufacturing means you could skip the freezer altogether --(Galapagos is doing this already) - And patients get treated faster. 3. >25% failure rates are not affordable. - Decentralized + automated systems allow faster retries when batches fail. - When time = survival, flexibility matters. - High OOS rates increase COGS that are already too high and put patients at risk 4. CGT economics only work if the process scales. - ZS estimates cost savings of up to 75% per batch when using automated, decentralized models at scale. - That’s how we can turn personalized cell therapy from niche to viable. - Even if the cost manufacturing was the same as centralized, reducing logistics costs/complexity and shorter vein-to-vein times make decentralized worth exploring 5. Regulatory alignment is the next step. - The paper calls for smarter master files, better digital/technology infrastructure, and a shift in how regulators define the “process = product” equation. - The tech is ready— we need policy to catch up.  The UK has already planted the decentralized flag, we need US and EU to follow. TLDR: - Autologous CAR-T is struggling to scale with centralized manufacturing - A decentralized, automated, modular model is a potential path forward - Cold chain and complex logistics isn’t helping enable access - The cost model is fixable with automation and flexible manufacturing models - The real bottleneck is mindset, not tech There is a new blueprint emerging for commercial viability in CGT. Let’s build. #celltherapy #cellandgenetherapy #biotechnology #manufacturingbrighterfuturestogether

🚀 🔬 Next-Gen CAR-T: Non-Viral Sleeping Beauty Transposons for Affordable and Scalable Cell Therapy 🔬💡 CAR-T therapies have transformed cancer treatment, but high costs, complex viral vector manufacturing, and safety concerns remain major obstacles. A new study introduces TranspoCART19, a Sleeping Beauty (SB) transposon-based CAR-T cell therapy that is cost-effective, scalable, and clinically viable, offering an alternative to conventional viral approaches. 🔎 What Makes TranspoCART19 a Game-Changer? ✅ Non-Viral Gene Delivery Instead of costly lentiviral or gamma-retroviral vectors, TranspoCART19 uses the SB transposon system, which integrates CAR constructs into T cells via electroporation, significantly reducing production costs (~10% of lentiviral costs) while maintaining efficacy. ✅ Optimized GMP Manufacturing for Scale-Up 🔹 Electroporation with MaxCyte ExPERT GTx ensures high transfection efficiency. 🔹 Expansion in G-Rex bioreactors allows reproducible large-scale CAR-T production. 🔹 Validated in multiple GMP facilities, ensuring robust and reproducible clinical manufacturing. ✅ Comparable Anti-Tumor Efficacy 🔹 In vitro & in vivo studies confirm that TranspoCART19 matches lentiviral CAR-T therapies in tumor-killing potency. 🔹 Demonstrates strong cytotoxic activity against CD19+ malignancies, including B-ALL and DLBCL. 🔹 High expansion & persistence observed in preclinical xenograft models. ✅ Enhanced Safety Profile 🔹 Lower vector copy number (VCN) per cell (5.16 copies/cell) reduces genotoxicity risk. 🔹 SB transposon integration is near-random, avoiding hotspots linked to oncogenesis. 🔹 No detectable transposase or residual transposon DNA in final CAR-T products. ✅ Built-in Safety Switch: hEGFRt for Controlled Elimination TranspoCART19 incorporates a truncated human EGFR (hEGFRt), allowing rapid depletion of CAR-T cells via cetuximab infusion—a critical safety feature for mitigating toxicity. 🏥 Clinical Translation Milestone: Phase I/IIa Trial Approved The Spanish Agency of Medicines and Medical Products (AEMPS) has approved a Phase I/IIa trial (NCT06378190) to evaluate TranspoCART19 in relapsed/refractory B-cell lymphomas (DLBCL, PCNSL, MCL, FL, and MZL). 🔹 Dose-escalation study (3+3 design) with three dose levels: 1, 3, and 5×10⁶ CAR-T cells/kg. 🔹 Manufacturing validated for both fresh & cryopreserved leukapheresis samples. 💡 Why Does This Matter? Current CAR-T therapies are transformative but financially unsustainable for widespread use. By eliminating viral vectors and streamlining manufacturing, SB transposon-based CAR-T products could make personalized immunotherapy significantly more accessible. 📢 Could non-viral gene transfer help expand the use of CAR-T therapy? #CART #GeneTherapy #CellTherapy #OncologyResearch #AdvancedTherapies #GMPManufacturing #CancerImmunotherapy

✨ 𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗔𝗔𝗩 𝗩𝗲𝗰𝘁𝗼𝗿 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗶𝗻𝗴 ✨ Adeno-Associated Virus vectors have emerged as a cornerstone of modern gene therapy, providing transformative potential for treating numerous genetic disorders. However, translating this potential into accessible treatments requires overcoming significant production hurdles. As presented in a recent review, the industry is transitioning toward more robust and scalable manufacturing frameworks to meet growing clinical demands. 🔹 𝗨𝗽𝘀𝘁𝗿𝗲𝗮𝗺 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻𝘀 • 𝘏𝘪𝘨𝘩-𝘋𝘦𝘯𝘴𝘪𝘵𝘺 𝘊𝘶𝘭𝘵𝘶𝘳𝘦𝘴: Implementation of N-1 perfusion processes and fixed-bed bioreactors has significantly increased cell densities and viral yields. • 𝘗𝘭𝘢𝘴𝘮𝘪𝘥 𝘌𝘯𝘨𝘪𝘯𝘦𝘦𝘳𝘪𝘯𝘨: The shift from traditional triple-plasmid transfection to advanced single- and dual-plasmid systems, such as the AAVone system, is reducing batch variability and enhancing productivity by up to 4-fold. • 𝘌𝘯𝘩𝘢𝘯𝘤𝘦𝘥 𝘛𝘳𝘢𝘯𝘴𝘧𝘦𝘤𝘵𝘪𝘰𝘯: Next-generation reagents and optimized DNA-to-reagent ratios are doubling viral titers while reducing the overall amount of required plasmid material. 🔹 𝗗𝗼𝘄𝗻𝘀𝘁𝗿𝗲𝗮𝗺 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗺𝗲𝗻𝘁𝘀 • 𝘊𝘢𝘱𝘴𝘪𝘥 𝘌𝘯𝘳𝘪𝘤𝘩𝘮𝘦𝘯𝘵: New serotype-agnostic affinity chromatography and ion-exchange methods are improving the critical separation of therapeutic full capsids from empty ones. • 𝘗𝘳𝘰𝘤𝘦𝘴𝘴 𝘊𝘰𝘯𝘵𝘳𝘰𝘭: Utilizing QbD frameworks and validated scale-down models ensures that CQAs remain consistent from laboratory to commercial scale. 🔹 𝗙𝘂𝘁𝘂𝗿𝗲 𝗗𝗶𝗿𝗲𝗰𝘁𝗶𝗼𝗻𝘀 • 𝘋𝘪𝘨𝘪𝘵𝘢𝘭 𝘛𝘳𝘢𝘯𝘴𝘧𝘰𝘳𝘮𝘢𝘵𝘪𝘰𝘯: The integration of Artificial Intelligence (AI) and predictive modeling will enable real-time monitoring of viral titers and automated process adjustments. • 𝘊𝘰𝘯𝘵𝘪𝘯𝘶𝘰𝘶𝘴 𝘔𝘢𝘯𝘶𝘧𝘢𝘤𝘵𝘶𝘳𝘪𝘯𝘨: Shifting away from batch processing toward continuous methodologies is expected to further expedite the delivery of personalized gene therapies. 🎯 𝗞𝗲𝘆 𝘁𝗮𝗸𝗲-𝗮𝘄𝗮𝘆𝘀: • 𝘚𝘤𝘢𝘭𝘢𝘣𝘪𝘭𝘪𝘵𝘺 𝘊𝘩𝘢𝘭𝘭𝘦𝘯𝘨𝘦𝘴: Traditional manufacturing often struggles with process variability and high development costs, necessitating a shift toward standardized, data-driven platforms. • 𝘘𝘶𝘢𝘭𝘪𝘵𝘺 𝘣𝘺 𝘋𝘦𝘴𝘪𝘨𝘯: Establishing Proven Acceptable Ranges (PAR) through rigorous process characterization is essential for regulatory compliance and product safety. • 𝘛𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘪𝘤𝘢𝘭 𝘚𝘺𝘯𝘦𝘳𝘨𝘺: Future gains in AAV productivity will likely stem from combining AI-driven analytics with intensified perfusion-based production. #GeneTherapy #AAV #Bioprocessing #Innovation #Pharmaceuticals Nandipati Charan Sai Sri Kowshik and Pushpendra Singh

Imagine gene therapy treatments costing $100,000 instead of $2 million per dose. A new review shows this isn't just wishful thinking – continuous bioprocessing could reduce manufacturing costs by up to 80%, potentially transforming patient access to these life-changing treatments. A exciting review paper by Lorek et al. reveals how the shift from traditional batch processing to continuous manufacturing may revolutionize gene therapy production. The innovation lies in running multiple production steps simultaneously with constant material flow, enabled by multi-column chromatography systems and advanced process analytic technology (PAT). What makes this particularly exciting is how continuous processing addresses the core challenges of gene therapy manufacturing. Traditional batch processing requires larger facilities, faces significant downtime between batches, and struggles with consistency. In contrast, continuous processing achieves higher productivity at a smaller scale while improving product quality – critical factors for reducing those astronomical million-dollar-plus treatment costs. The technology behind this transformation is fascinating. Multi-column chromatography systems now enable continuous capture and purification of viral vectors, improving productivity nearly threefold while maintaining yields above 82%. Even more impressive is the integration of real-time monitoring through process analytical technologies. These systems use in -line spectroscopic sensors, dynamic light scattering, and rapid analytics to track critical quality attributes in real-time, ensuring consistent product quality while dramatically reducing manufacturing time and costs. The implications for patient care are profound. By reducing facility footprint, increasing productivity, and improving product quality, continuous processing could help transform gene therapies from last-resort options into more widely accessible treatments. Early studies suggest manufacturing costs could drop by 60-80% compared to traditional batch processing – a game-changing reduction that could dramatically expand patient access. What excites me most is how these advances are converging with artificial intelligence and automation. Real-time monitoring systems coupled with advanced process controls are enabling unprecedented precision in manufacturing, ensuring every batch meets the highest quality standards while maximizing efficiency. We're witnessing a fundamental shift in how gene therapies are manufactured. The question isn't just about cost reduction – it's about reimagining production to make these transformative treatments accessible to everyone who needs them. What are your thoughts on these developments? How do you see these manufacturing innovations reshaping the future of genetic medicine? #GeneTherapy #Biotechnology #ContinuousProcessing #Healthcare #Innovation #PatientAccess

Too often, cell therapy developers choose 𝗼𝗽𝗲𝗻 𝗽𝗿𝗼𝗰𝗲𝘀𝘀𝗲𝘀 for flexibility, only to face the consequences later. While open workflows may seem practical at first, they carry 𝘀𝗶𝗴𝗻𝗶𝗳𝗰𝗮𝗻𝘁 𝗵𝗶𝗱𝗱𝗲𝗻 𝗰𝗼𝘀𝘁𝘀. The FDA emphasizes closed systems wherever feasible to reduce contamination risk. Today, I break down the cost, complexity, and scale limitations inherent to open processes. 𝗜𝗻𝗳𝗿𝗮𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲 𝗮𝗻𝗱 𝗖𝗹𝗲𝗮𝗻𝗿𝗼𝗼𝗺 𝗖𝗼𝘀𝘁 Open processes require work in Grade A spaces (e.g., BSC) within a Grade B background, which cost 𝟯𝟬 - 𝟰𝟬% 𝗺𝗼𝗿𝗲 𝗽𝗲𝗿 𝘀𝗾𝗳𝘁 than the Grade C or D cleanrooms used for closed systems and require more advanced HVAC, gowning, and environmental monitoring, further driving up operating expenses. 𝗖𝗼𝗻𝘁𝗮𝗺𝗶𝗻𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗕𝗮𝘁𝗰𝗵 𝗙𝗮𝗶𝗹𝘂𝗿𝗲 𝗥𝗶𝘀𝗸 While contamination rates for CAR-T are not widely reported, data from 𝗼𝗽𝗲𝗻 autologous stem cell workflows show rates from 𝟬.𝟲 - 𝟭𝟯%, underscoring the risk of manual, open processing. When each batch represents a patient, a single contamination event can cost hundreds of thousands of dollars in product loss, delayed treatment, and regulatory impacts. Closed systems using sterile, single-use fluid paths eliminate environmental exposure, resulting in 𝗻𝗲𝗮𝗿-𝘇𝗲𝗿𝗼 𝗰𝗼𝗻𝘁𝗮𝗺𝗶𝗻𝗮𝘁𝗶𝗼𝗻 and greater process reliability. 𝗩𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻 𝗖𝗼𝗺𝗽𝗹𝗲𝘅𝗶𝘁𝘆 Open processes require 𝘀𝗲𝗽𝗮𝗿𝗮𝘁𝗲 𝘃𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻 for each instrument and manual step, including IQ/OQ/PQ, cleaning validation, aseptic simulations, and SOPs, all of which add to QA workload and documentation. Closed systems are often validated as an integrated unit, simplifying GMP onboarding. 𝗧𝗲𝗰𝗵 𝗧𝗿𝗮𝗻𝘀𝗳𝗲𝗿 𝗮𝗻𝗱 𝗥𝗲𝗽𝗿𝗼𝗱𝘂𝗰𝗶𝗯𝗶𝗹𝗶𝘁𝘆 Open processes almost always depend on manual interventions, making tech transfer across sites or CDMOs difficult. Operator variability drives inconsistencies, increasing the 𝗿𝗶𝘀𝗸 𝗼𝗳 𝗱𝗲𝘃𝗶𝗮𝘁𝗶𝗼𝗻𝘀, 𝗯𝗮𝘁𝗰𝗵 𝗳𝗮𝗶𝗹𝘂𝗿𝗲𝘀, 𝗮𝗻𝗱 𝗲𝘅𝘁𝗲𝗻𝗱𝗲𝗱 𝗯𝗿𝗶𝗱𝗴𝗶𝗻𝗴 𝘀𝘁𝘂𝗱𝗶𝗲𝘀. Closed systems offer standardized, reproducible workflows that simplify transfer. 𝗣𝗿𝗼𝗰𝗲𝘀𝘀 𝗦𝗰𝗮𝗹𝗮𝗯𝗶𝗹𝗶𝘁𝘆 Open processes scale inefficiently. Each batch adds to demand on cleanroom space, scheduling, and QA, creating bottlenecks as volume grows. Operator multitasking is limited by the need to maintain sterility and documentation during parallel open steps. Closed systems reduce manual handling and environmental dependence, enabling parallel batch processing with less staff and space, which is key for early trials and distributed models. 𝗡𝗼𝘁 𝗮𝗹𝗹 𝗚𝗠𝗣-𝗰𝗼𝗺𝗽𝗹𝗶𝗮𝗻𝘁 𝗽𝗿𝗼𝗰𝗲𝘀𝘀𝗲𝘀 𝗮𝗿𝗲 𝗚𝗠𝗣-𝗿𝗲𝗮𝗱𝘆, and the earlier you think about that, the better. Whether you're still optimizing your preclinical workflow or preparing for IND, I’m happy to share my perspective on how to simplify, close, or future-proof your process.

The best of two worlds -combining extracellular vesicles and liposomes for enhanced biocompatibility Naturally occurring extracellular vesicles (EVs) offer an intriguing alternative to traditional LNPs as native, safe, and multifunctional nanovesicle carriers. Still, unlike more of their lipid-based counterparts, they typically struggle with the loading of large biomolecules like mRNA. Addressing this challenge, a quite recent study introduces an innovative controlled loading technique that marries the biocompatibility of EVs with the robust delivery capabilities of LNPs. The method involves DNA-mediated and programmed fusion between EVs and mRNA-loaded liposomes, enhancing the delivery and expression of therapeutic RNA. Using real-time microscopy, the authors characterized the fusion efficiency at the single-particle level, a process that was facilitated by immobilizing EV surfaces through lipidated biotin-DNA handles/ Following successful fusion, the resultant EV-liposome particles (known as EVLs) were collected using a DNA strand-replacement reaction, ensuring the integrity and functionality of the vesicles. In functional tests, EVLs encapsulating mCherry mRNA showed superior transfection and translation efficiencies in HEK293-H cells compared to traditional liposomes or LNPs, underscoring the potential of EVLs as a significant advancement in the delivery of RNA therapeutics. Beyond initial results, one of the most interesting aspects of this research is the scalability of EVL production -by transferring the fusion reaction to magnetic beads, the team managed to increase production levels by a factor of one million, demonstrating the potential for large-scale manufacturing of these hybrid nanovesicles. One additional aspect to mention is the ability for the synthesis of biomimetic EVLs to be multiplexed -multiple origins of EVs can be functionalized with specific lipidated DNA (LiNAs) and fused together with specific antisense LiNA-decorated liposomes in a one-pot experiment for multiplexed target-specific and bioactive cargo delivery. In this way, biomimetic EVLs may contribute to the ever-rising demand for the delivery of modern biologicals, addressing the complexity and heterogeneity of many diseases where treatment options are still limited or associated with major side effects. Learn more here: https://lnkd.in/ezmn4U7c #nanoparticles #lipidnanoparticles #evs #drugdelivery #rnadelivery #rnatherapeutics #nanomedicine #nanotech #nanomaterials #genetherapy

The future of cell therapy manufacturing lies in digitization and Industry 4.0 technologies. As advanced therapies move from clinical development to commercialization, traditional manual processes can no longer keep pace with the demand for scalability, consistency, and regulatory compliance. By integrating Manufacturing Execution Systems (MES), AI-driven analytics, real-time monitoring, and automated quality control, we can transform cell therapy manufacturing into a more efficient, reproducible, and scalable process. Technologies such as digital twins, process analytical technologies (PAT), and augmented reality (AR) for operator training are paving the way for a smarter, more connected manufacturing environment. Industry 4.0 is not just about automation—it’s about intelligent decision-making, predictive process control, and reducing variability in cell therapy production. The convergence of AI, IoT, and cloud-based solutions is ensuring that every batch meets the highest quality standards, improving patient outcomes while making these life-saving therapies more accessible. The question is no longer if digitization will transform cell therapy manufacturing, but how quickly we can embrace and implement these innovations to advance the field. The time to act is now!

Cell and gene therapy hasn’t stalled, but scaling it remains hard for reasons that have little to do with the science. In working with programs moving from clinic to commercial, a consistent pattern shows up in that delays and setbacks are driven far more often by manufacturing, analytical variability, tech transfer, and data integrity than by biology. FDA feedback over the past few years reinforces that reality, the process really is the product. I wrote this piece, Improving Cell and Gene Therapy Scale-Up with a Digital-First Approach, for Contract Pharma to unpack where programs most often run into trouble during scale-up, and how a digital-first manufacturing approach can reduce those risks. It looks at practical levers, from closed and automated systems to integrated data, digital twins, and real-time release strategies, that can help programs scale with more confidence and regulatory credibility. Find the full article linked in the comments below.

3 steps to improve your AAV production yields (without changing your downstream processes) 65% of gene therapies in development use AAVs. Achieving high AAV yields is crucial for the success and scalability of gene therapies. Here are three key strategies to increase AAV yields: 1. Culture medium composition Optimise the growth medium to provide the necessary nutrients for cell growth and AAV production. Serum-free or low-serum media formulations are preferred because they reduce the risk of impurities and improve the consistency of AAV production. 2. Culture conditions Fine-tune and monitor culture conditions to create the optimal growth environment. Consider implementing fed-batch or perfusion strategies to renew nutrients and remove waste products. 3. Supplementation and additives Evaluate the impact of supplementing the culture medium with additives such as lipids, antioxidants, or specific growth factors. Make sure to test and optimise concentrations for best results. By combining these strategies, you can optimise culture conditions to achieve higher AAV production yields, ultimately enhancing the manufacturing efficiency and scalability of AAV-based gene therapies. Do you use any of these strategies in your manufacturing process? YES/NO #Bioprocessing #CellManufacturing #AAV #GeneTherapy

🧪 Thermo Fisher Scientific #Launches #CTS #DynaXS™ #Bioreactor to Scale Cell Therapy Manufacturing A strategic infrastructure move targeting one of the biggest bottlenecks in cell therapy: scalable, cGMP-ready manufacturing 1️⃣ From static culture → scalable bioprocessing • Introduces Gibco™ CTS™ DynaXS™ Single-Use Bioreactor • Stirred-tank system for controlled cell expansion • Supports process development → clinical production ➡️ Addresses the core challenge: 👉 how to scale without losing consistency 2️⃣ Built for real-world manufacturing constraints • Single-use design → reduces contamination risk + cleaning burden • Flexible volumes across development stages • Automation-ready + cGMP-aligned ➡️ Enables faster tech transfer from lab to clinic 3️⃣ Integrated into full CTS ecosystem • Connects upstream (cell isolation/activation) → expansion → downstream • Unified platform + regulatory documentation ➡️ Not just a product — a workflow strategy 4️⃣ Expanding beyond oncology drives complexity • Cell therapies now moving into autoimmune + new indications • Different cell types require different process configurations ➡️ Platform designed for multi-modality manufacturing flexibility 🧩 My takeaway Cell therapy is no longer limited by science — it’s limited by manufacturing scalability and reproducibility What Thermo Fisher Scientific is doing here is positioning itself as: 👉 the “AWS of cell therapy manufacturing infrastructure” Owning the platform layer (not just reagents) means: • deeper customer lock-in • higher long-term value capture • critical role in commercialization success 📌 Bottom line The CTS DynaXS™ launch reinforces that the next wave of cell therapy winners won’t just be drug developers — they’ll be companies that solve how to manufacture at scale, reliably and compliantly #CellTherapy #Biomanufacturing #Biotech #GMP https://lnkd.in/e75Mb7uc